Generic OxyContin Availability

OxyContin is a brand name of oxycodone, approved by the FDA in the following formulation(s):

OXYCONTIN (oxycodone hydrochloride - tablet, extended release;oral)

  • Manufacturer: PURDUE PHARMA LP
    Approval date: April 5, 2010
    Strength(s): 10MG, 15MG, 20MG, 30MG, 40MG [RLD], 60MG, 80MG

Has a generic version of OxyContin been approved?

No. There is currently no therapeutically equivalent version of OxyContin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of OxyContin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Hot-melt extrudable pharmaceutical formulation
    Patent 6,488,963
    Issued: December 3, 2002
    Inventor(s): James W.; McGinity & Feng; Zhang
    Assignee(s): The University of Texas System
    The present invention relates to pharmaceutical formulations comprising a hot-melt extrudable mixture of a therapeutic compound and a high molecular weight poly(ethylene oxide) in an essentially non-film like preparation. In some embodiments, the formulation further comprises poly(ethylene glycol). The present invention also includes efficient methods for hot-melt extruding pharmaceutical formulations in essentially non-film preparations.
    Patent expiration dates:
    • June 24, 2017
      ✓ 
      Drug product
  • Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
    Patent 7,674,799
    Issued: March 9, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:
    • March 30, 2025
      ✓ 
      Drug product
  • Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
    Patent 7,674,800
    Issued: March 9, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:
    • March 30, 2025
      ✓ 
      Drug substance
  • Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
    Patent 7,683,072
    Issued: March 23, 2010
    Inventor(s): Chapman; Robert & Rider; Lonn S. & Hong; Qi & Kyle; Donald & Kupper; Robert
    Assignee(s): Purdue Pharma L.P.
    In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Patent expiration dates:
    • March 30, 2025
      ✓ 
      Drug substance
  • Abuse-proofed dosage system
    Patent 7,776,314
    Issued: August 17, 2010
    Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich
    Assignee(s): Grunenthal GmbH
    The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Patent expiration dates:
    • April 19, 2025
      ✓ 
      Drug product
  • Abuse-proofed dosage form
    Patent 8,114,383
    Issued: February 14, 2012
    Inventor(s): Bartholomäus; Johannes & Kugelmann; Heinrich & Arkenau-Marić; Elisabeth
    Assignee(s): Gruenenthal GmbH
    The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Patent expiration dates:
    • October 10, 2024
      ✓ 
      Drug product
  • Abuse-proofed dosage form
    Patent 8,309,060
    Issued: November 13, 2012
    Inventor(s): Bartholomaus; Johannes & Kugelmann; Heinrich & Arkenau-Marić; Elisabeth
    Assignee(s): Grunenthal GmbH
    An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Patent expiration dates:
    • November 20, 2023
      ✓ 
      Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
      ✓ 
      Drug product
  • Pharmaceutical formulation containing gelling agent
    Patent 8,337,888
    Issued: December 25, 2012
    Inventor(s): Wright; Curtis & Oshlack; Benjamin & Breder; Christopher
    Assignee(s): Purdue Pharma L.P.
    Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Patent expiration dates:
    • August 6, 2022
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)